Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency

Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.